{"meta":{"query_hash":"5858a2241443","filters":{"venue":"Clinical Medicine Insights Therapeutics"},"cohort_total":15,"direct_labels_cover":0,"predictions_cover":15,"exported":15,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5858a2241443","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Medicine+Insights+Therapeutics"},"results":[{"id":"W1965329525","doi":"10.4137/cmt.s4012","title":"Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Laboratory of Public Health; University of Alberta","funders":"","keywords":"Varenicline; Smoking cessation; Medicine; Comorbidity; Psychiatry; Mental illness; Addiction; Nicotine replacement therapy; Pharmacotherapy; Nicotine; Tolerability; Mental health; Internal medicine; Adverse effect","score_opus":0.05322821542743384,"score_gpt":0.37534411572994764,"score_spread":0.3221159003025138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965329525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938854,0.000088171415,0.00016110156,0.0033995735,0.0014221254,0.00036648018,0.000001257985,0.00006273084,0.00061317487],"genre_scores_gemma":[0.9956408,0.0003015333,0.00016010454,0.002953836,0.0008105161,0.000009911878,0.00007276643,0.00002955806,0.000020965883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974945,0.00012218206,0.0008401255,0.00040052744,0.00092096935,0.00022165528],"domain_scores_gemma":[0.9981997,0.0006644823,0.0002164061,0.00039812332,0.00022762433,0.00029366714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008944968,0.000208953,0.00050641526,0.00020748276,0.000083780644,0.000012366987,0.00013000163,0.0004749813,0.00023943423],"category_scores_gemma":[0.0005825753,0.00012935587,0.000047291156,0.00042391865,0.00053447793,0.00009420368,0.000033465065,0.0014572295,0.0000018180118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002733763,0.00060832064,0.94887316,0.00002203201,0.000038316317,0.00001629747,0.00019484412,1.18579166e-7,0.000014180167,0.00023631481,0.000058022197,0.049665034],"study_design_scores_gemma":[0.0106035145,0.0012954,0.98411685,0.00021972833,0.00031371004,0.00001627506,0.000052727504,0.00014370555,0.000024413755,0.00052732404,0.0025299548,0.00015637939],"about_ca_topic_score_codex":0.00004035876,"about_ca_topic_score_gemma":0.00011427326,"teacher_disagreement_score":0.049508654,"about_ca_system_score_codex":0.00002646244,"about_ca_system_score_gemma":0.00014377535,"threshold_uncertainty_score":0.63310176},"labels":[],"label_agreement":null},{"id":"W1981981010","doi":"10.4137/cmt.s5884","title":"Efficacy and Safety of Galantamine Hydrobromide in the Treatment of Mild to Moderate Dementia","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Galantamine; Dementia; Mood; Placebo; Medicine; Nausea; Psychiatry; Disease; Internal medicine; Donepezil; Alternative medicine","score_opus":0.08946186334557535,"score_gpt":0.4202218599304458,"score_spread":0.33075999658487043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981981010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125564,0.0008875127,0.00012090929,0.0045615705,0.00016496419,0.0011319078,0.0000032601185,0.00000867917,0.0018655842],"genre_scores_gemma":[0.994188,0.0037257627,0.0002412919,0.0014693943,0.00021278638,0.000022919245,0.000013533404,0.0000141739665,0.00011210426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979269,0.00021200972,0.0009365943,0.0002758378,0.00041888235,0.00022979302],"domain_scores_gemma":[0.9977483,0.0013657378,0.00013817352,0.0004181614,0.00016396077,0.0001656808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007907799,0.00017718785,0.000653769,0.00015857803,0.000041296254,0.0000046979776,0.00014373577,0.00011373002,0.00009456436],"category_scores_gemma":[0.00017246975,0.000090063404,0.00008433645,0.00028317687,0.00058409467,0.000026396072,0.000029520055,0.00029731618,0.0000045385646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012205691,0.014495022,0.66372603,0.00022794977,0.0016024486,0.00011494402,0.009664385,0.0000035756284,0.08996363,0.0015447562,0.00022084758,0.2062307],"study_design_scores_gemma":[0.017247373,0.017787207,0.9299123,0.00027340793,0.0007770715,0.00001804448,0.00036010105,0.0003658222,0.012847941,0.00053484726,0.019750241,0.00012561542],"about_ca_topic_score_codex":0.00004624311,"about_ca_topic_score_gemma":0.00008734601,"teacher_disagreement_score":0.26618627,"about_ca_system_score_codex":0.000011798938,"about_ca_system_score_gemma":0.000071599505,"threshold_uncertainty_score":0.3672679},"labels":[],"label_agreement":null},{"id":"W1989502045","doi":"10.4137/cmt.s3783","title":"Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lapatinib; Trastuzumab; Breast cancer; Cancer research; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Metastatic breast cancer; Cancer; Targeted therapy; Pertuzumab; Letrozole; Oncology; Internal medicine; Receptor; Tamoxifen","score_opus":0.18813864389023785,"score_gpt":0.4205964844946525,"score_spread":0.23245784060441463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989502045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402804,0.0034767236,0.00008578692,0.008040126,0.0007047638,0.0011682558,0.000068313006,0.00006630378,0.0023617009],"genre_scores_gemma":[0.98587966,0.002799896,0.0015934297,0.008247524,0.0010684179,0.00010392742,0.000032636042,0.0000894745,0.00018501024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561256,0.00041550788,0.0018029172,0.00083338044,0.00074102666,0.00059463555],"domain_scores_gemma":[0.99661493,0.00096634874,0.00029944882,0.0008687962,0.0004891451,0.0007613144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009217748,0.0004055147,0.0014054594,0.00033188422,0.000055950826,0.000010464709,0.00030865296,0.00045686885,0.00081539433],"category_scores_gemma":[0.00053699245,0.00029656064,0.0001325081,0.0007770206,0.0008615247,0.000056653487,0.00019653808,0.0010579894,0.000026903796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079604685,0.0039112996,0.70064384,0.000657806,0.0011976447,0.0008598748,0.027942803,0.0000035518558,0.0699002,0.0006806348,0.00316946,0.18307242],"study_design_scores_gemma":[0.013587725,0.0067991274,0.93150735,0.0035850534,0.0005789172,0.000060021808,0.0018348596,0.00035260964,0.023557331,0.0025945308,0.014802751,0.00073969987],"about_ca_topic_score_codex":0.007467125,"about_ca_topic_score_gemma":0.002485818,"teacher_disagreement_score":0.23086353,"about_ca_system_score_codex":0.00013806287,"about_ca_system_score_gemma":0.000499358,"threshold_uncertainty_score":0.9999487},"labels":[],"label_agreement":null},{"id":"W2005153650","doi":"10.4137/cmt.s3567","title":"Risperidone for Individuals with Refractory Schizophrenia","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Risperidone; Schizophrenia (object-oriented programming); Refractory (planetary science); Antipsychotic; Clozapine; Psychiatry; Atypical antipsychotic; Medicine; Psychology","score_opus":0.08233823778095527,"score_gpt":0.40706287697328014,"score_spread":0.32472463919232486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005153650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980854,0.0012809925,0.0004874127,0.013086077,0.0009810216,0.0015160447,0.00001369807,0.000166235,0.0016145639],"genre_scores_gemma":[0.9640198,0.00079958345,0.027082836,0.0037734779,0.0033187286,0.00015834383,0.00008888136,0.00008695597,0.00067141996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972832,0.00010231066,0.0008231121,0.0006023001,0.0006922005,0.0004968288],"domain_scores_gemma":[0.99586517,0.0018390223,0.00021981257,0.0009396048,0.00041974007,0.00071663345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069988734,0.00035630923,0.00088661246,0.00020212894,0.000182389,0.000023511117,0.00025172427,0.0003632491,0.00028951615],"category_scores_gemma":[0.00060675497,0.00019114431,0.00019948148,0.00030756136,0.0011437997,0.00008763807,0.00004564262,0.0012851943,0.00007772406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08829377,0.0064824917,0.18223949,0.00030148297,0.005335095,0.0005099818,0.0011188686,5.0854703e-7,0.015883097,0.030178675,0.0077495524,0.66190696],"study_design_scores_gemma":[0.072160035,0.025992528,0.22588506,0.0004389148,0.0018772723,0.0002602799,0.00021648714,0.0002270138,0.0036029941,0.012445358,0.65627563,0.00061845203],"about_ca_topic_score_codex":0.00001758656,"about_ca_topic_score_gemma":0.00014548106,"teacher_disagreement_score":0.66128856,"about_ca_system_score_codex":0.00003463789,"about_ca_system_score_gemma":0.0005440733,"threshold_uncertainty_score":0.7794639},"labels":[],"label_agreement":null},{"id":"W2007434442","doi":"10.4137/cmt.s4670","title":"Effectiveness and Safety of Rizatriptan Benzoate 10 mg in the Treatment of Migraine Headaches","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; GDI Integrated Facility Services (Canada); Merck Canada Inc. (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Rizatriptan; Medicine; Migraine; Nausea; Headaches; Somnolence; Adverse effect; Anesthesia; Triptans; Prospective cohort study; Internal medicine; Sumatriptan; Surgery","score_opus":0.09138714600609213,"score_gpt":0.407207713880599,"score_spread":0.31582056787450685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007434442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851877,0.006985574,0.00002392826,0.0048422418,0.00010796207,0.0007695446,0.0000053155327,0.000013497679,0.0020642544],"genre_scores_gemma":[0.9893422,0.009278645,0.00014592803,0.00054302835,0.00039441235,0.000017870685,0.000010981564,0.000017199241,0.00024972504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979162,0.0003043197,0.0010169642,0.00027807764,0.00028823726,0.00019617697],"domain_scores_gemma":[0.9956538,0.003360899,0.000224777,0.00049048924,0.00017481078,0.00009520147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010471264,0.00023245395,0.0011255773,0.00012387914,0.000056923218,0.0000021838675,0.00012090007,0.00019585322,0.00005149276],"category_scores_gemma":[0.00037064365,0.000111229434,0.00018503008,0.00031150848,0.001249383,0.000024064382,0.00002084898,0.00035556627,0.000001559026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011900979,0.01137991,0.6559703,0.0019484059,0.002890681,0.00015959537,0.052995082,0.0000012647012,0.0956441,0.011786608,0.0014547659,0.15386832],"study_design_scores_gemma":[0.011576666,0.013510053,0.84597296,0.00048648778,0.00094664586,0.00003179817,0.001624921,0.00009378036,0.0033678613,0.0019480936,0.12027298,0.00016776755],"about_ca_topic_score_codex":0.00012669714,"about_ca_topic_score_gemma":0.0003909668,"teacher_disagreement_score":0.19000266,"about_ca_system_score_codex":0.000014847883,"about_ca_system_score_gemma":0.00007550188,"threshold_uncertainty_score":0.46034035},"labels":[],"label_agreement":null},{"id":"W2013609844","doi":"10.4137/cmt.s4500","title":"Gastric Acid-Related Diseases: Focus on Esomeprazole","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Esomeprazole; Omeprazole; Medicine; Rabeprazole; Gastroenterology; Proton-pump inhibitor; Clopidogrel; Internal medicine; Gastric acid; Famotidine; Helicobacter pylori; Aspirin; Stomach","score_opus":0.04990391487098689,"score_gpt":0.3820149494845545,"score_spread":0.3321110346135676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013609844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773163,0.0008676988,0.00006344138,0.0043854686,0.002600836,0.00067046034,0.000009470206,0.00025168352,0.013834621],"genre_scores_gemma":[0.9911297,0.00036864742,0.00032037278,0.005487669,0.0013773766,0.000024985637,0.00006482957,0.00006659058,0.0011598249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710447,0.00012967222,0.001045185,0.0006131366,0.00063622475,0.00047134515],"domain_scores_gemma":[0.99705046,0.0007375709,0.00025064935,0.00097193307,0.00018227378,0.0008071045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026902344,0.00040651977,0.0008817239,0.00022458471,0.000138702,0.000014621812,0.0002388915,0.00039358984,0.00065035356],"category_scores_gemma":[0.00054156623,0.00024031136,0.00029679594,0.00045535038,0.0007102627,0.000067244444,0.000050601586,0.0014155583,0.00068694307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001619655,0.00886513,0.54203296,0.00009462317,0.0022267767,0.004345449,0.0007267814,0.0000022097174,0.008168927,0.009874704,0.0030164544,0.41902632],"study_design_scores_gemma":[0.02574539,0.015388268,0.90596527,0.00031678338,0.002940912,0.00029450952,0.000089545836,0.00037267918,0.0024790158,0.019672483,0.026351867,0.00038326223],"about_ca_topic_score_codex":0.0000042108923,"about_ca_topic_score_gemma":0.0000031197653,"teacher_disagreement_score":0.41864306,"about_ca_system_score_codex":0.00004187118,"about_ca_system_score_gemma":0.00014832709,"threshold_uncertainty_score":0.9799613},"labels":[],"label_agreement":null},{"id":"W2015849975","doi":"10.4137/cmt.s7586","title":"Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Mitoxantrone; Medicine; Cardiotoxicity; Multiple sclerosis; Tolerability; Internal medicine; Oncology; Ejection fraction; Natalizumab; Disease; Adverse effect; Chemotherapy; Heart failure; Immunology","score_opus":0.3327976076464534,"score_gpt":0.39962326133547466,"score_spread":0.06682565368902127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015849975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881307,0.0029726247,0.000067627385,0.0009444034,0.00081757974,0.0019578047,0.000009577266,0.00021255016,0.004887135],"genre_scores_gemma":[0.993537,0.0023180635,0.0010587927,0.0016400461,0.0010871936,0.00018018683,0.00001390064,0.00008646212,0.0000783609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99474245,0.00070665724,0.0017649474,0.00093069766,0.0009683638,0.00088686927],"domain_scores_gemma":[0.99554735,0.0017907255,0.0003594895,0.0010601553,0.00062130543,0.00062094466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010440958,0.0005257595,0.0016550339,0.0004245525,0.00018321266,0.000017067436,0.00043977724,0.00054471404,0.00029552096],"category_scores_gemma":[0.002584534,0.00035787787,0.0003151799,0.00088401564,0.0013821987,0.00016740618,0.00023270705,0.0019797315,0.00007112803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004563356,0.002922707,0.5492953,0.00026240307,0.0019766146,0.00065433834,0.01062298,2.8346793e-7,0.10517175,0.00007081167,0.00050566747,0.32395375],"study_design_scores_gemma":[0.012278609,0.003907289,0.9634115,0.0009181071,0.00026553764,0.000016360234,0.0006420275,0.00026284103,0.016437206,0.00016691507,0.0013251884,0.00036839012],"about_ca_topic_score_codex":0.0003678306,"about_ca_topic_score_gemma":0.00018816104,"teacher_disagreement_score":0.4141162,"about_ca_system_score_codex":0.00016968918,"about_ca_system_score_gemma":0.00033819178,"threshold_uncertainty_score":0.99988735},"labels":[],"label_agreement":null},{"id":"W2029911300","doi":"10.4137/cmt.s2213","title":"Emerging Therapies for the Management of Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada); Health Sciences Centre","funders":"","keywords":"Medicine; Multiple sclerosis; Data extraction; Clinical trial; MEDLINE; Cochrane Library; Randomized controlled trial; Placebo; Transplantation; Intensive care medicine; Internal medicine; Alternative medicine; Pathology; Immunology","score_opus":0.27042793296101914,"score_gpt":0.44032114106798154,"score_spread":0.1698932081069624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029911300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183064,0.011430894,0.0063474216,0.05101983,0.0040686466,0.0048271418,0.000018139226,0.00019174488,0.0037897867],"genre_scores_gemma":[0.9701657,0.020640448,0.0054265116,0.0019739012,0.001177054,0.00018178175,0.000008276774,0.00004801932,0.0003782963],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974266,0.00008946418,0.0010531417,0.0003931907,0.0006516992,0.00038587215],"domain_scores_gemma":[0.99328303,0.0048337653,0.0002649401,0.00094745244,0.00049963855,0.00017116338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013775687,0.00025567084,0.0007249187,0.00010707222,0.00027564215,0.0000109339435,0.00041505398,0.00016461212,0.00011645927],"category_scores_gemma":[0.00057922956,0.00012657845,0.00031167577,0.00032143694,0.0016730267,0.000047600515,0.00014039429,0.00068121846,0.000008994468],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012591616,0.0008934192,0.028290818,0.0005685274,0.004896452,0.0000067529663,0.0029969928,0.000003088491,0.058442846,0.0041116364,0.0021989455,0.89633137],"study_design_scores_gemma":[0.013175385,0.0019978797,0.5424583,0.00094504596,0.0015983027,0.000005095369,0.004292895,0.004499706,0.00514912,0.001406148,0.42416194,0.0003101809],"about_ca_topic_score_codex":0.000020535503,"about_ca_topic_score_gemma":0.000038693714,"teacher_disagreement_score":0.8960212,"about_ca_system_score_codex":0.000016106938,"about_ca_system_score_gemma":0.000044785294,"threshold_uncertainty_score":0.6164337},"labels":[],"label_agreement":null},{"id":"W2049767450","doi":"10.4137/cmt.s4120","title":"Intranasal Ciclesonide in Allergic Rhinitis","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ciclesonide; Medicine; Nasal administration; Nasal spray; Asthma; Dermatology; Immunology; Inhaled corticosteroids","score_opus":0.07250437245537755,"score_gpt":0.37392661891136175,"score_spread":0.3014222464559842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049767450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95770174,0.0005341647,0.00044397303,0.01985713,0.002173785,0.00042909777,0.0000012592873,0.00011913464,0.018739702],"genre_scores_gemma":[0.9764078,0.003107983,0.0009133273,0.017090889,0.0020007205,0.000008407508,0.0000426666,0.000049761482,0.00037843524],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728525,0.00016080524,0.0012825188,0.00046406145,0.0004533073,0.00035403177],"domain_scores_gemma":[0.99794847,0.000766117,0.00018212956,0.00055346865,0.00021958447,0.00033024498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006685875,0.00026526448,0.00078555953,0.00020694177,0.000077182056,0.000014034986,0.00016963459,0.0004542451,0.0005991318],"category_scores_gemma":[0.00043516373,0.00018633899,0.000139372,0.0003879858,0.00070620474,0.00008580723,0.00003568286,0.0014521428,0.000075519325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034842654,0.0052743424,0.21855585,0.00026437308,0.0012718984,0.006585348,0.014191713,0.000026192683,0.06915248,0.081175275,0.014749107,0.58526915],"study_design_scores_gemma":[0.01926533,0.0034865667,0.49375308,0.00069207,0.0003925236,0.00070755294,0.0012128858,0.009545475,0.0011684566,0.015868636,0.453099,0.0008083922],"about_ca_topic_score_codex":0.000042795826,"about_ca_topic_score_gemma":0.00039431587,"teacher_disagreement_score":0.58446074,"about_ca_system_score_codex":0.000028290751,"about_ca_system_score_gemma":0.00015996984,"threshold_uncertainty_score":0.7598684},"labels":[],"label_agreement":null},{"id":"W2069864063","doi":"10.4137/cmt.s11675","title":"Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bedaquiline; Tuberculosis; Multiple drug resistance; Isoniazid; Antibiotics; Drug resistance; Internal medicine; Intensive care medicine; Clinical trial; Incidence (geometry); Mycobacterium tuberculosis; Microbiology; Pathology; Biology","score_opus":0.10248851677833781,"score_gpt":0.41540600339063316,"score_spread":0.31291748661229535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069864063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693295,0.006557122,0.000030122019,0.021200508,0.00012327945,0.0011476376,0.0000042244005,0.000013869538,0.0015937902],"genre_scores_gemma":[0.9601102,0.036187135,0.00026983174,0.0030237387,0.00027495998,0.000031391453,0.000018304738,0.000019390562,0.00006503331],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964517,0.00079170783,0.0016809623,0.00035193682,0.0003786068,0.00034510225],"domain_scores_gemma":[0.9913066,0.0073333713,0.00025584476,0.00067072856,0.00021241634,0.00022104579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009979544,0.00024010766,0.0012719936,0.00016988168,0.00004828187,0.0000035371113,0.00019003815,0.00024430652,0.00010162633],"category_scores_gemma":[0.00097158615,0.00011154034,0.00020103608,0.00031742232,0.0013007729,0.000043009393,0.00003062861,0.00034855612,0.000012902262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008458662,0.01296814,0.40633497,0.00047841787,0.0027635798,0.0001307035,0.016511008,0.000014176506,0.02673994,0.0043936023,0.0017827207,0.5194241],"study_design_scores_gemma":[0.011596528,0.012857532,0.93861514,0.00030506635,0.00050193485,0.000023643992,0.0010703186,0.0016539557,0.00075452594,0.0009151757,0.03156049,0.00014567],"about_ca_topic_score_codex":0.00089080597,"about_ca_topic_score_gemma":0.00013640111,"teacher_disagreement_score":0.5322802,"about_ca_system_score_codex":0.000050902625,"about_ca_system_score_gemma":0.000073002775,"threshold_uncertainty_score":0.4792752},"labels":[],"label_agreement":null},{"id":"W2084281139","doi":"10.4137/cmt.s4456","title":"Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Carboplatin; Ovarian cancer; Doxorubicin; Paclitaxel; Drug; Oncology; Pharmacology; Internal medicine; Cancer; Chemotherapy; Cisplatin","score_opus":0.08930760328561985,"score_gpt":0.4170289362062235,"score_spread":0.3277213329206037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084281139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9432202,0.0024940264,0.00002847158,0.038811874,0.0017759181,0.0010432743,0.00000426474,0.00003560578,0.012586392],"genre_scores_gemma":[0.9866125,0.0051094466,0.00057198596,0.0065552485,0.00083335483,0.000086632084,0.00001252218,0.000026607055,0.0001916953],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99773175,0.00013412458,0.0010189374,0.00037299102,0.0004740974,0.0002680857],"domain_scores_gemma":[0.9981964,0.0005427193,0.00022682133,0.00077774253,0.00012471015,0.00013160825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006595929,0.00023066433,0.0006532323,0.00011260758,0.000051995623,0.000007794372,0.00027533225,0.00021812532,0.00039541852],"category_scores_gemma":[0.000027975406,0.00011720523,0.00014882915,0.00049486716,0.0004874389,0.00003645724,0.000040103183,0.0007644237,0.000015238452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017865939,0.007841141,0.3646468,0.00060683786,0.0040455614,0.001415723,0.0068637915,0.000007864273,0.0047434787,0.06277757,0.0020646688,0.54319996],"study_design_scores_gemma":[0.011559384,0.0018560059,0.8854603,0.00093959866,0.0016802764,0.000038356244,0.0006639452,0.00017608554,0.0010412767,0.0023764246,0.094011545,0.00019675592],"about_ca_topic_score_codex":0.00019481852,"about_ca_topic_score_gemma":0.00021610007,"teacher_disagreement_score":0.5430032,"about_ca_system_score_codex":0.000034836565,"about_ca_system_score_gemma":0.000101015816,"threshold_uncertainty_score":0.47794905},"labels":[],"label_agreement":null},{"id":"W2275755947","doi":"10.4137/cmt.s18886","title":"Stroke Prevention with Percutaneous Left Atrial Appendage Closure","year":2016,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Atrial fibrillation; Left atrial appendage occlusion; Percutaneous; Stroke (engine); Cardiology; Internal medicine; Thrombus; Occlusion; Thromboembolic stroke; Atrial Appendage; Thrombosis; Warfarin","score_opus":0.15231308163768636,"score_gpt":0.4183604860180196,"score_spread":0.26604740438033325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275755947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93109155,0.0014011218,0.007416347,0.045915112,0.0023004317,0.0014996823,0.0000064091155,0.00034380422,0.010025538],"genre_scores_gemma":[0.96756375,0.0016740545,0.00078985764,0.0018029526,0.006339328,2.4350882e-7,0.000021596063,0.000051451894,0.021756763],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974251,0.00021771196,0.00097225286,0.0004542683,0.00063216366,0.00029850917],"domain_scores_gemma":[0.99755406,0.0011729004,0.00030082942,0.0005451964,0.00018745496,0.00023954184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052841706,0.00028356715,0.0007816218,0.0001403515,0.00010531284,0.000013380768,0.00015093604,0.00025576993,0.00089242705],"category_scores_gemma":[0.00030126004,0.00012890591,0.00036818712,0.00015245678,0.00050520565,0.00011250649,0.00004779822,0.00027074205,0.00017289823],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067018433,0.00009937765,0.8168716,0.000088619934,0.002063162,0.00045472902,0.0005717902,0.0000032334858,0.0063141016,0.004309368,0.0016306269,0.16089159],"study_design_scores_gemma":[0.017630138,0.010255725,0.10784845,0.000813366,0.0029494849,0.00038483573,0.00032291425,0.00008052293,0.0003732304,0.0030170833,0.8558216,0.0005026638],"about_ca_topic_score_codex":0.0000031607399,"about_ca_topic_score_gemma":0.000015991447,"teacher_disagreement_score":0.85419095,"about_ca_system_score_codex":0.0000528408,"about_ca_system_score_gemma":0.00011352852,"threshold_uncertainty_score":0.977145},"labels":[],"label_agreement":null},{"id":"W2759644066","doi":"10.1177/1179559x17731801","title":"Brexpiprazole in the Treatment of Major Depressive Disorder","year":2017,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network; St. Michael's Hospital","funders":"Ontario Brain Institute; Massachusetts General Hospital","keywords":"Partial agonist; Aripiprazole; PsycINFO; Major depressive disorder; Adjunctive treatment; Antipsychotic; Antidepressant; Medicine; Meta-analysis; Psychology; Atypical antipsychotic; Psychiatry; Psychotherapist; MEDLINE; Schizophrenia (object-oriented programming); Agonist; Internal medicine; Anxiety; Mood; Receptor","score_opus":0.1311998809784387,"score_gpt":0.4398751764897023,"score_spread":0.3086752955112636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759644066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664819,0.0077016465,0.00006108542,0.017242802,0.00059253006,0.0009590642,0.0000032889989,0.0000291595,0.006928489],"genre_scores_gemma":[0.99018574,0.006960316,0.00016138378,0.00141969,0.00067225046,0.00005485824,0.000015846768,0.000028829194,0.00050107983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779993,0.00021540649,0.00088348845,0.0003750914,0.0004763868,0.00024972137],"domain_scores_gemma":[0.9963407,0.001168845,0.00050442206,0.0017555807,0.00010807238,0.00012240376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030145748,0.00026868188,0.0008179337,0.0000962936,0.00021251594,0.000016533448,0.00044685995,0.0002207941,0.00007885721],"category_scores_gemma":[0.00028402283,0.000121089986,0.00020908273,0.000089913476,0.0009867674,0.00008549713,0.000041371117,0.00026662217,0.000022531847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010892788,0.0070025073,0.6805428,0.000055383633,0.00051437155,0.00037032703,0.004517832,0.0000015289363,0.0011527189,0.0007288582,0.00040440768,0.30361998],"study_design_scores_gemma":[0.022677425,0.0070148744,0.8675395,0.00044454483,0.00092340243,0.00003587588,0.0005339351,0.00013706562,0.0015896097,0.0019319137,0.09701106,0.00016074535],"about_ca_topic_score_codex":0.00016891901,"about_ca_topic_score_gemma":0.00012462845,"teacher_disagreement_score":0.30345923,"about_ca_system_score_codex":0.000043692435,"about_ca_system_score_gemma":0.00007302463,"threshold_uncertainty_score":0.49379066},"labels":[],"label_agreement":null},{"id":"W2761151032","doi":"10.1177/1179559x17734227","title":"Efficacy of Continuous Positive Airway Pressure Treatment in Patients with Cardiac Arrhythmia and Obstructive Sleep Apnea: What is the Evidence?","year":2017,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Obstructive Sleep Apnea Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Continuous positive airway pressure; Obstructive sleep apnea; Cardiology; Cardiac arrhythmia; Internal medicine; Observational study; Heart failure; Positive airway pressure; Ejection fraction; Confounding; Coronary artery disease; Sleep apnea; Intensive care medicine; Atrial fibrillation","score_opus":0.051850662150654536,"score_gpt":0.36904719783004464,"score_spread":0.3171965356793901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761151032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97851694,0.009056369,0.000028802473,0.008766029,0.0006175966,0.0025697818,0.000014713823,0.00001636466,0.00041338574],"genre_scores_gemma":[0.9960609,0.00247666,0.00012305196,0.0005178267,0.00060725014,0.000043246717,0.000009836951,0.000043037995,0.0001181531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968137,0.00046959976,0.0008446164,0.0006669238,0.00081501267,0.00039011412],"domain_scores_gemma":[0.9937209,0.0033027993,0.00057404255,0.0014199478,0.0007282051,0.00025414547],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00054134044,0.0003800241,0.0013007257,0.00012201256,0.00026048816,0.00006380885,0.0003366935,0.000255092,0.00003115834],"category_scores_gemma":[0.00081161136,0.0001833136,0.00016867039,0.0001651226,0.0034372867,0.0003888578,0.00015093753,0.0006540547,0.000005399945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049425447,0.0004631802,0.5546551,0.00005496611,0.0018588052,0.000043771903,0.005968557,0.0000011273996,0.0000965692,0.00014156125,0.0000074035956,0.43176645],"study_design_scores_gemma":[0.012818585,0.008099739,0.97207993,0.0010577748,0.0014187647,0.0000060705775,0.0012985797,0.00020066611,0.0011058884,0.00019065487,0.0015302743,0.00019309756],"about_ca_topic_score_codex":0.00011719151,"about_ca_topic_score_gemma":0.000017028095,"teacher_disagreement_score":0.43157333,"about_ca_system_score_codex":0.000095279596,"about_ca_system_score_gemma":0.00008509839,"threshold_uncertainty_score":0.9992748},"labels":[],"label_agreement":null},{"id":"W96046762","doi":"10.4137/cmt.s9566","title":"Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Polycythaemia; Medicine; Food and drug administration; Clinical trial; Janus kinase; Janus kinase 2; Internal medicine; Pharmacology; Bone marrow","score_opus":0.15977028268133486,"score_gpt":0.4327420877786614,"score_spread":0.27297180509732655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W96046762","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28784496,0.3647003,0.0010856655,0.2743152,0.003007551,0.026074855,0.00016481844,0.00041188556,0.042394776],"genre_scores_gemma":[0.5271199,0.41870755,0.003402041,0.04502639,0.0017942014,0.0024750337,0.0001912273,0.000093215975,0.0011904696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973589,0.00017144604,0.0014292743,0.00046318115,0.0002748898,0.0003022866],"domain_scores_gemma":[0.9956258,0.002403573,0.0003679517,0.0006880891,0.0005829849,0.00033161486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028752824,0.0003590624,0.0013947284,0.00010800274,0.000091814516,0.0000069313096,0.000112749156,0.00018458809,0.00055700145],"category_scores_gemma":[0.00039367707,0.00019299526,0.0004547017,0.000199461,0.0003707437,0.000047660622,0.00001792357,0.000180863,0.00012598645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014988757,0.01488151,0.018890895,0.007568026,0.005868421,0.00003071299,0.0013112823,0.0000029030164,0.0018803129,0.0835445,0.055021953,0.80950063],"study_design_scores_gemma":[0.024410311,0.0950009,0.044477504,0.043404553,0.0056543644,0.000047282574,0.00030793552,0.00033283056,0.009847821,0.018047111,0.7577847,0.0006846518],"about_ca_topic_score_codex":0.00004327562,"about_ca_topic_score_gemma":0.0000054982484,"teacher_disagreement_score":0.80881596,"about_ca_system_score_codex":0.00013800967,"about_ca_system_score_gemma":0.00019984951,"threshold_uncertainty_score":0.7870118},"labels":[],"label_agreement":null}]}